Turnstone Biologics CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Turnstone Biologics Corp. is set to merge with XOMA Royalty Corporation, discontinuing all clinical programs and reducing its workforce to three employees, with a potential liquidation if the merger fails.
Turnstone Biologics discontinues clinical trials and seeks strategic alternatives due to financial constraints, raising concerns about its future.
Turnstone Biologics reported its Q3 2024 financial results, alongside a strategic pipeline prioritization and a 60% workforce reduction to focus on TIDAL-01.
Turnstone Biologics reports a net loss of $40.9 million for the first half of 2024, while highlighting positive preliminary data from its TIDAL-01 clinical trial.
Turnstone Biologics reported a net loss of $19.6 million for the first quarter of 2024, compared to a net income of $0.1 million for the same period in 2023, while continuing to advance its clinical programs.